Business Context and Reporting Period
Company: Prana Biotechnology Limited (Note: Metadata lists "Alterity Therapeutics Ltd," but the filing text identifies the registrant as Prana Biotechnology Limited).
Filing Type: Form 6-K (Preliminary Final Report).
Reporting Period: Financial year ended June 30, 2002.
Filing Date: December 23, 2002.
Business Overview: The entity operates in a single geographic location and industry, primarily focused on biotechnology research and development. The company reported no revenue from sales or services, deriving income solely from interest and other relevant revenue sources.
Key Financial Metrics
| Metric | Current Period (FY 2002) | Prior Period (FY 2001) |
|---|---|---|
| Revenue (Ordinary Activities) | $793,970 | $516,182 |
| Net Loss (Attributable to Members) | $(5,304,236) | $(4,138,980) |
| Operating Expenses | $(6,098,206) | $(4,655,162) |
| Research & Development Costs | $(2,479,945) | $(2,362,917) |
| Legal Fees | $(823,201) | $(252,675) |
| Cash and Cash Equivalents (End of Period) | $3,585,014 | $6,854,873 |
| Total Assets | $17,581,319 | $22,314,743 |
| Total Liabilities | $(912,332) | $(921,866) |
| Net Tangible Asset Backing per Share | 5.09 cents | 11.5 cents |
| Earnings Per Share (Basic & Diluted) | (9.2) cents | (7.8) cents |
Material Changes vs. Prior Period
- Revenue Growth: Revenue from ordinary activities increased by 54% to $793,970, driven primarily by a rise in "Other relevant revenue" from $226,000 to $567,250. Interest revenue declined slightly.
- Increased Loss: The net loss attributable to members widened by 28% to $(5,304,236). This was due to a 31% increase in total expenses from ordinary activities.
- Expense Drivers: Significant increases were observed in Legal Fees (up 226% to $823,201), Wages (up 210% to $378,853), and Consulting Fees (up 50% to $460,643).
- Liquidity Decline: Cash holdings decreased by approximately 48% from $6.85 million to $3.59 million. Net operating cash flow was negative $(3,799,515), compared to $(2,360,315) in the prior period.
- Financing Activity: The company raised $580,345 through the issue of securities, a significant decrease from $4.75 million raised in the prior period.
Outlook, Risks, and Contingencies
- Management Commentary: Directors reported no material factors affecting revenues or expenses other than those disclosed. There were no comments on seasonal or irregular factors.
- Contingent Liabilities: The filing notes no change in the status of the matter regarding "PN Gerolymatos" since the last annual report, other than what was previously disclosed in public announcements.
- Dividends: No dividends were declared or paid for the current or prior period.
- Post-Period Events: No events occurred since the end of the reporting period that had a material effect on the financial position.
- Audit Status: The accounts were in the process of being audited or subject to review at the time of filing.
Investor Verification Checklist
- Identity Discrepancy: Verify the relationship between the metadata name "Alterity Therapeutics Ltd" and the filing registrant "Prana Biotechnology Limited."
- Cash Burn Rate: Assess the sustainability of operations given the negative operating cash flow of $(3.8M) and the 48% reduction in cash reserves.
- Legal Exposure: Investigate the nature of the "PN Gerolymatos" matter and the 226% spike in legal fees to understand potential litigation risks.
- Revenue Quality: Analyze the composition of the $567,250 "Other relevant revenue" to determine if it is recurring or one-off (e.g., grants, which totaled $843,714 in cash flow).
- Dilution Risk: Review the outstanding options (approx. 27.7 million options at $0.50 exercise price) relative to the 58.6 million ordinary shares issued.